Healthcare Industry News: vorinostat
News Release - January 22, 2013
Clinical Trials Advancing Proton Therapy Research Open at the CDH Proton Center, A ProCure Center
Trials to assess proton therapy for pediatric and prostate cancersWARRENVILLE, Ill.--(Healthcare Sales & Marketing Network)--Six clinical trials, including one evaluating the effectiveness of proton beam therapy in treating children with specific brain cancers and three proton therapy trials for men with prostate cancer, are being led by researchers at CDH Proton Center, A ProCure Center.
The trials are evaluating the effectiveness of proton therapy, both on its own and in comparison to – plus in combination with – other treatment options.
“We recently returned from a national medical meeting where more than 70 papers and posters were presented assessing the effectiveness of proton therapy, and the results continue to be impressive,” said Dr. William Hartsell, the Center’s medical director. “Our clinical trials are part of a national effort to assess new and what we anticipate will be better ways to treat patients with proton therapy.”
One of the prostate cancer trials (identifier code: NCT01230866) is exploring the effectiveness of treating patients using higher doses of proton therapy treatment over a much shorter time period (five treatments over one to two weeks) than current standards (44 treatments over as many as nine weeks). A second prostate cancer trial looks at the impact of combining hormone (androgen deprivation) therapy with proton therapy (code: NCT01492972).
Another clinical trial (code: NCT00867178) will assess the effectiveness of a combination of proton therapy and chemotherapy for infants born with tumors of the central nervous system, such as medulloblastoma and ependymoblastoma.
“We hope to learn more about the effectiveness and potential benefits of treating patients with proton therapy in new ways or combined with other important treatments,” Hartsell said.
Proton therapy is an advanced form of radiation treatment for many cancerous and non-cancerous tumors, including tumors of the brain, central nervous system, head and neck, lung and prostate, as well as sarcomas and many pediatric cancers. The precision of proton therapy makes it especially effective for treating children and adults with anatomically complex tumors such as base of skull and tumors along the spinal cord.
To learn more about proton therapy and the CDH Proton Center, A ProCure Center, go to http://www.procure.com/il.
To learn more about all six clinical trials, go to http://www.clinicaltrials.gov and search for the following identifier codes:
- NCT01230866 (“Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer”)
- NCT01492972 (“Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer”)
- NCT00867178 (“vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System”)
- NCT01088035 (“Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma”)
- NCT01255748 (“Registry Study for Proton Therapy Outcomes”)
- NCT01603420 (“External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer”)
In addition to these trials, the Center is also working with collaborating institutions on several studies that allow for the use of proton therapy, including:
- NCT00085735 (“A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial”)
- NCT00392327 (“Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients”)
- NCT00653068 (“Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation”)
- NCT01602666 (“Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors”)
- NCT01602666 (“Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors”)
- NCT01182350 (“Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas”)
- NCT01222754 (“A Phase I Trial of Lenalidomide and Radiotherapy in children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas“)
About CDH Proton Center, A ProCure Center
CDH Proton Center, A ProCure Center, Warrenville, Ill., is one of a handful of facilities in the country that offer proton therapy, an advanced form of radiation to treat cancer. The four-room, 60,000 sq. ft. Center, opened Oct. 19, 2010, is the first for Illinois and has the capacity to treat up to 1,500 patients a year. The precision of proton therapy spares healthy tissue and results in fewer short- and long-term side effects than treatment with standard X-ray radiation therapy. Proton therapy has been shown to be beneficial in the treatment of a broad range of tumor types including head and neck, brain, central nervous system, prostate, lung, sarcomas, gastrointestinal and many pediatric cancers. It is especially effective for treating children and adults with anatomically complex tumors such as at the base of the skull and tumors along the spinal cord. The CDH Proton Center, A ProCure Center, is a collaboration between Central DuPage Hospital (CDH), Radiation Oncology Consultants (ROC) and ProCure Treatment Centers, Inc. ProCure was founded in 2005 in Bloomington, Ind., and is developing a network of proton therapy centers in cities across the United States. For more information, visit www.procure.com/il.
Source: ProCure Treatment Centers
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
